Biomarker panels of Aβ 42/40, p-tau, and measures of neurodegeneration such as neurofilament light (NfL) [27] combined with the APOE genotype may eventually be shown to be sufficiently accurate to diagnose AD without requiring CSF or PET confirmation. This evidence concerns the gene MAPT and Alzheimer disease.